Abemaciclib + Letrozole
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Oct 10, 2020 → Dec 31, 2026
NCT ID
NCT04393285About Abemaciclib + Letrozole
Abemaciclib + Letrozole is a phase 2 stage product being developed by Eli Lilly for Endometrial Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04393285. Target conditions include Endometrial Cancer.
What happened to similar drugs?
0 of 20 similar drugs in Endometrial Cancer were approved
Approved (0) Terminated (0) Active (20)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05872204 | Phase 2 | Recruiting |
| NCT04393285 | Phase 2 | Active |
Competing Products
20 competing products in Endometrial Cancer